United Therapeutics Co. (NASDAQ:UTHR – Get Rating) EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $189.18, for a total transaction of $1,135,080.00. Following the transaction, the executive vice president now owns 36,397 shares of the company’s stock, valued at approximately $6,885,584.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of UTHR traded down $2.59 during midday trading on Friday, hitting $187.63. The stock had a trading volume of 377,924 shares, compared to its average volume of 448,792. United Therapeutics Co. has a 1 year low of $158.38 and a 1 year high of $218.38. The firm has a market cap of $8.47 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 7.39 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.61 and a quick ratio of 7.30. The stock’s 50 day moving average is $182.81 and its 200 day moving average is $193.23.
United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The biotechnology company reported $2.35 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.77 by ($1.42). The company had revenue of $415.20 million during the quarter, compared to analysts’ expectations of $427.59 million. United Therapeutics had a return on equity of 12.80% and a net margin of 28.23%. The company’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.19 EPS. As a group, equities research analysts expect that United Therapeutics Co. will post 14.04 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in United Therapeutics by 3.7% in the 4th quarter. State Street Corp now owns 1,517,265 shares of the biotechnology company’s stock worth $327,851,000 after buying an additional 54,462 shares during the period. Bank of New York Mellon Corp increased its stake in United Therapeutics by 17.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 844,958 shares of the biotechnology company’s stock worth $155,962,000 after buying an additional 123,295 shares during the period. Deutsche Bank AG increased its stake in United Therapeutics by 542.3% in the 3rd quarter. Deutsche Bank AG now owns 843,437 shares of the biotechnology company’s stock worth $155,681,000 after buying an additional 712,117 shares during the period. Geode Capital Management LLC increased its stake in United Therapeutics by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 760,948 shares of the biotechnology company’s stock worth $164,425,000 after buying an additional 62,882 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its stake in United Therapeutics by 4.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 731,390 shares of the biotechnology company’s stock worth $158,039,000 after buying an additional 29,292 shares during the period. 96.46% of the stock is currently owned by institutional investors.
About United Therapeutics (Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.